Animax

Manufacturer
Dechra Veterinary Products
Effective date
2026-03-24
Label type
PRESCRIPTION ANIMAL DRUG LABEL
Version
9
Source
full-release
Hydrated at
2026-06-01 02:46:45

Label at a glance#

ProductAnimax
Active ingredientNYSTATIN, NEOMYCIN SULFATE, THIOSTREPTON, TRIAMCINOLONE ACETONIDE
Label structure13 sections

Dosage and administration

Frequency of administration is dependent on the severity of the condition. For mild inflammations, application may range from once daily to once a week; for severe conditions Animax Ointment may be applied as often as two to three times daily, if necessary. Frequency of treatment may be decreased as improvement occurs. Wear gloves during the administration of the ointment or wash hands immediately after applicatio...

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

VETERINARY

For use in dogs and cats only.

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

DESCRIPTION:

DESCRIPTION SECTION

Animax Ointment combines nystatin, neomycin sulfate, thiostrepton and triamcinolone acetonide in a non-irritating polyethylene and mineral oil base.

Each mL contains:
nystatin 100,000 units
neomycin sulfate equivalent to neomycin base 2.5 mg
thiostrepton 2,500 units
triamcinolone acetonide 1 mg

The preparation is intended for local therapy in a variety of cutaneous disorders of dogs and cats; it is especially useful in disorders caused, complicated, or threatened by bacterial and/or candidal (monilial) infection.

ACTIONS:

SPL UNCLASSIFIED SECTION

By virtue of its four active ingredients, Animax Ointment provides four basic therapeutic effects: anti-inflammatory, antipruritic, antifungal and antibacterial. Triamcinolone acetonide is a potent synthetic corticosteroid providing rapid and prolonged symptomatic relief on topical administration. Inflammation, edema, and pruritus promptly subside, and lesions are permitted to heal. Nystatin is the first well-tolerated antifungal antibiotic of dependable efficacy for the treatment of cutaneous infections caused by Candida albicans (Monilia). Nystatin is fungistatic in vitro against a variety of yeast and yeast-like fungi including many fungi pathogenic to animals. No appreciable activity is exhibited against bacteria. Thiostrepton has a high order of activity against gram-positive organisms, including many which are resistant to other antibiotics; neomycin exerts antimicrobial action against a wide range of gram-positive and gram-negative bacteria. Together they provide comprehensive therapy against those organisms responsible for most superficial bacterial infections.

WARNINGS:

WARNINGS SECTION

Clinical and experimental data have demonstrated that corticosteroids administered orally or by injection to animals may induce the first stage of parturition if used during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis.

Additionally, corticosteroids administered to dogs, rabbits and rodents during pregnancy have resulted in cleft palate in the offspring. In dogs, other congenital anomalies have resulted: deformed forelegs, phocomelia, and anasarca.

Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away.

INDICATIONS:

INDICATIONS & USAGE SECTION

Animax Ointment is particularly useful in the treatment of acute and chronic otitis of varied etiologies, in interdigital cysts in cats and dogs and in anal gland infections in dogs.

The preparation is also indicated in the management of dermatologic disorders characterized by inflammation and dry or exudative dermatitis, particularly those caused, complicated, or threatened by bacterial or candidal (Candida albicans) infections. It is also of value in eczematous dermatitis, contact dermatitis, and seborrheic dermatitis; and as an adjunct in the treatment of dermatitis due to parasitic infestation.

PRECAUTIONS:

PRECAUTIONS SECTION

Animax Ointment is not intended for the treatment of deep abscesses or deep-seated infections such as inflammation of the lymphatic vessels. Parenteral antibiotic therapy is indicated in these infections.

Animax Ointment has been extremely well tolerated. Cutaneous reactions attributable to its use have been extremely rare. The occurrence of systemic reactions is rarely a problem with topical administration. There is some evidence that corticosteroids can be absorbed after topical application and cause systemic effects. Therefore, an animal receiving Animax Ointment therapy should be observed closely for signs such as polydipsia, polyuria, and increased weight gain.

Animax Ointment is not generally recommended for the treatment of deep or puncture wounds or serious burns.

Sensitivity to neomycin may occur. If redness, irritation, or swelling persists or increases, discontinue use. Do not use if pus is present since the drug may allow the infection to spread.

Avoid ingestion. Oral or parenteral use of corticosteroids (depending on dose, duration of use, and specific steroid) may result in inhibition of endogenous steroid production following drug withdrawal.

SIDE EFFECTS:

ADVERSE REACTIONS SECTION

SAP and SGPT (ALT) enzyme elevations, polydipsia and polyuria, vomiting, and diarrhea (occasionally bloody) have been observed following parenteral or systemic use of synthetic corticosteroids in dogs.

Cushing's syndrome has been reported in association with prolonged or repeated steroid therapy in dogs. Temporary hearing loss has been reported in conjunction with treatment of otitis with products containing corticosteroids. However, regression usually occurred following withdrawal of the drug. Hearing loss, with varying degrees of recovery, has been reported with the use of Animax Ointment. If hearing dysfunction is noted during the course of treatment with Animax Ointment, discontinue its use.

To report suspected adverse drug events, for technical assistance or to obtain a copy of the safety data sheet (SDS), contact Dechra at (866) 933-2472.

For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at www.fda.gov/reportanimalae.

CAUTION:

CONTRAINDICATIONS SECTION

Before instilling any medication into the ear, examine the external ear canal thoroughly to be certain the tympanic membrane is not ruptured in order to avoid the possibility of transmitting infection to the middle ear as well as damaging the cochlea or vestibular apparatus from prolonged contact. If hearing or vestibular dysfunction is noted during the course of treatment, discontinue the use of Animax Ointment.

DOSAGE AND ADMINISTRATION:

DOSAGE & ADMINISTRATION SECTION

Frequency of administration is dependent on the severity of the condition. For mild inflammations, application may range from once daily to once a week; for severe conditions Animax Ointment may be applied as often as two to three times daily, if necessary.

Frequency of treatment may be decreased as improvement occurs.

Wear gloves during the administration of the ointment or wash hands immediately after application.

Otitis

Clean ear canal of impacted cerumen. Inspect canal and remove any foreign bodies such as grass awns, ticks, etc. Instill three to five drops of Animax Ointment.

Preliminary use of a local anesthetic may be advisable.

Infected Anal Glands, Cystic Areas, etc.

Drain gland or cyst and then fill with Animax Ointment.

Other Dermatologic Disorders

Clean affected areas, removing any encrusted discharge or exudate. Apply Animax Ointment sparingly in a thin film.

HOW SUPPLIED:

HOW SUPPLIED SECTION

Animax Ointment is supplied in tubes as follows:

7.5 mL tubes NDC 17033-122-75
15 mL tubes NDC 17033-122-15
30 mL tubes NDC 17033-122-30

STORAGE: Store at room temperature; avoid excessive heat (104°F).

TO OPEN:

SPL UNCLASSIFIED SECTION

Use cap to puncture seal.

instructions
instructions

IMPORTANT:

SPL UNCLASSIFIED SECTION

The opening of this product is covered by a metal tamper-evident seal.

If this seal has been punctured or is not visible, do not use and return product to place of purchase.

Approved by FDA under NADA # 140-847

MANUFACTURED FOR:
Dechra Veterinary Products

Overland Park, KS 66211 USA

MANUFACTURED BY:
Fougera Pharmaceuticals Inc.

Melville, NY 11747 USA

46269508 Rev. 01/2023

PRINCIPAL DISPLAY PANEL - 7.5 mL Carton

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Animax® Ointment
(nystatin-neomycin sulfate-thiostrepton-triamcinolone acetonide ointment)
NET CONTENTS 7.5 mL
NDC 17033-122-75

carton
carton

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
2105780neomycin 2.5 MG / nystatin 100,000 UNT / thiostrepton 2500 UNT / triamcinolone acetonide 1 MG per 1 GM Topical OintmentPSN9
2105780neomycin 0.025 MG/MG / nystatin 100 UNT/MG / thiostrepton 2.5 UNT/MG / triamcinolone 0.001 MG/MG Topical OintmentSCD9
2105780neomycin 2.5 MG / nystatin 100,000 UNT / thiostrepton 2500 UNT / triamcinolone acetonide 1 MG per 1 GM Topical OintmentSY9

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
d4d7da1a-7fd4-628e-cdae-89e749b1c534Product name720260127
e29fe634-dc25-094c-c77f-5d09c3eceb3eProduct name520260107
75f7e47b-8736-a182-fc44-22aca8d79689Product name220251211
62986c8d-91f1-b1ba-b5a3-8b54b75bb8c2Product name620250516
e42f429b-c4e5-0402-e1c5-730154df4060Product name420240205
e57b6340-9387-3f9a-7307-511c81791375Product name320221214
38d4de13-64b3-4057-b91c-4b5126962341Product name120220516
544f8e8d-6389-eeeb-9586-aa447c08dcc7Product name520210614
089e0644-1ea8-8654-4113-39f960dd57d5Product name320210115
1629e00f-54fb-4a43-8306-b58442b23902Product name920200430
5331c9c8-f64b-11e6-ccf1-071c477fcb0bProduct name720190612
854ec07b-1cd7-a5db-235a-7aa24d3cf97aProduct name320180628
9f64e0dc-109c-9660-8e0e-91ec987b3817Product name620171204
dfa879a3-32de-49f0-a7ba-9b9c3e13002fProduct name120171204
8de20f81-8411-4cf1-a8b2-03404ee56d01Product name320171109
99e684e6-f435-feb8-d2bb-3a546f1cb768Product name220161117
a5f1a68c-0352-4f34-46a3-9b4eed239ed8Product name220160819
19b9f4c1-15e9-edcc-4c16-f01ecfb5c549Product name120140508
355b2224-0895-7135-83f5-d099a6a82a0aProduct name120140508
55be6b50-8cc0-f0f1-74a1-3416a91193aaProduct name120140508
7a0092d1-1e8c-0d78-4f8d-d95fa15cc3cfProduct name120140508
89b93c13-4be8-69f3-b33b-63e64feffb9bProduct name120140508
b045ad64-0f28-9a02-2f9b-b34d94fb2278Product name120140508
b6082387-f592-1148-0844-bd068fd213fbProduct name120140508

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
17033-122-15Animax1 in 1 CARTONOINTMENT19
17033-122-15Animax15 mL in 1 TUBEOINTMENT159
17033-122-30Animax30 mL in 1 TUBEOINTMENT309
17033-122-30Animax1 in 1 CARTONOINTMENT19
17033-122-75Animax7.5 mL in 1 TUBEOINTMENT7.59
17033-122-75Animax1 in 1 CARTONOINTMENT19

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
NEOMYCIN SULFATEACTIVE INGREDIENT057Y6266933
NYSTATINACTIVE INGREDIENTBDF1O1C72E3
THIOSTREPTONACTIVE INGREDIENTHR4S203Y183
TRIAMCINOLONE ACETONIDEACTIVE INGREDIENTF446C597KA3
NEOMYCINACTIVE MOIETYI16QD7X2973
NYSTATINACTIVE MOIETYBDF1O1C72E3
THIOSTREPTONACTIVE MOIETYHR4S203Y183
TRIAMCINOLONE ACETONIDEACTIVE MOIETYF446C597KA3
HIGH DENSITY POLYETHYLENEINACTIVE INGREDIENTUG00KM4WR73
MINERAL OILINACTIVE INGREDIENTT5L8T28FGP3

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 9 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
17033-12217033-122-75, 17033-122-15, 17033-122-30

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 6 matching rows.

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 1 · 48 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
MINERAL OILMINERAL OILT5L8T28FGPTABLET, COATED / ORAL1.5 mgExact identifier — unii candidate
30 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPOINTMENT / AURICULAR (OTIC)NAExact identifier — unii candidate
30 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPTABLET, EXTENDED RELEASE / ORALNAExact identifier — unii candidate
30 equally ranked IID candidates
HIGH DENSITY POLYETHYLENEHIGH DENSITY POLYETHYLENEUG00KM4WR7TABLET / ORAL50 mgExact identifier — unii candidate
18 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPSYSTEM / TOPICAL654.36 mgExact identifier — unii candidate
30 equally ranked IID candidates
HIGH DENSITY POLYETHYLENEHIGH DENSITY POLYETHYLENEUG00KM4WR7TABLET, DELAYED RELEASE / ORALNAExact identifier — unii candidate
18 equally ranked IID candidates
HIGH DENSITY POLYETHYLENEHIGH DENSITY POLYETHYLENEUG00KM4WR7TABLET, EXTENDED RELEASE / ORAL0.64 mgExact identifier — unii candidate
18 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPCAPSULE / ORAL120 mgExact identifier — unii candidate
30 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPOINTMENT / OPHTHALMIC59.5 %w/wExact identifier — unii candidate
30 equally ranked IID candidates
HIGH DENSITY POLYETHYLENEHIGH DENSITY POLYETHYLENEUG00KM4WR7CAPSULE, EXTENDED RELEASE / ORAL4.53 mgExact identifier — unii candidate
18 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPTABLET, CHEWABLE / ORAL6 mgExact identifier — unii candidate
30 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPCAPSULE, EXTENDED RELEASE / ORAL120 mgExact identifier — unii candidate
30 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPLOTION / TOPICAL1428 mgExact identifier — unii candidate
30 equally ranked IID candidates
HIGH DENSITY POLYETHYLENEHIGH DENSITY POLYETHYLENEUG00KM4WR7CAPSULE / ORAL10 mgExact identifier — unii candidate
18 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPPASTE / DENTAL95 %w/wExact identifier — unii candidate
30 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPSUSPENSION / TOPICAL82 %w/wExact identifier — unii candidate
30 equally ranked IID candidates
HIGH DENSITY POLYETHYLENEHIGH DENSITY POLYETHYLENEUG00KM4WR7PASTE / TOPICAL2.5 %w/wExact identifier — unii candidate
18 equally ranked IID candidates
HIGH DENSITY POLYETHYLENEHIGH DENSITY POLYETHYLENEUG00KM4WR7TABLET, COATED / ORAL25 mgExact identifier — unii candidate
18 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPOIL / TOPICAL43.29 %v/vExact identifier — unii candidate
30 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPSUPPOSITORY / VAGINAL30 mgExact identifier — unii candidate
30 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPFILM, EXTENDED RELEASE / TRANSDERMAL34 mgExact identifier — unii candidate
30 equally ranked IID candidates
HIGH DENSITY POLYETHYLENEHIGH DENSITY POLYETHYLENEUG00KM4WR7SUPPOSITORY / VAGINALNAExact identifier — unii candidate
18 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPTABLET, DELAYED RELEASE / ORAL5.67 mgExact identifier — unii candidate
30 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPTABLET / ORAL113.75 mgExact identifier — unii candidate
30 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPOINTMENT / TOPICAL9938 mgExact identifier — unii candidate
30 equally ranked IID candidates
HIGH DENSITY POLYETHYLENEHIGH DENSITY POLYETHYLENEUG00KM4WR7TAPE / TOPICALNAExact identifier — unii candidate
18 equally ranked IID candidates
HIGH DENSITY POLYETHYLENEHIGH DENSITY POLYETHYLENEUG00KM4WR7FILM, EXTENDED RELEASE / TRANSDERMAL85 mgExact identifier — unii candidate
18 equally ranked IID candidates
HIGH DENSITY POLYETHYLENEHIGH DENSITY POLYETHYLENEUG00KM4WR7SUPPOSITORY / RECTALNAExact identifier — unii candidate
18 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPFILM / TRANSDERMAL11.42 mgExact identifier — unii candidate
30 equally ranked IID candidates
HIGH DENSITY POLYETHYLENEHIGH DENSITY POLYETHYLENEUG00KM4WR7CREAM / TOPICAL54.5 %w/wExact identifier — unii candidate
18 equally ranked IID candidates
HIGH DENSITY POLYETHYLENEHIGH DENSITY POLYETHYLENEUG00KM4WR7GEL / TOPICAL26 %w/wExact identifier — unii candidate
18 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPSUSPENSION / AURICULAR (OTIC)0.5 %w/vExact identifier — unii candidate
30 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPSUPPOSITORY / RECTALNAExact identifier — unii candidate
30 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPDROPS / ORALNAExact identifier — unii candidate
30 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPCREAM / TOPICAL2772 mgExact identifier — unii candidate
30 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPTABLET, FILM COATED / ORALNAExact identifier — unii candidate
30 equally ranked IID candidates
HIGH DENSITY POLYETHYLENEHIGH DENSITY POLYETHYLENEUG00KM4WR7OINTMENT / OPHTHALMICNAExact identifier — unii candidate
18 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPCREAM / VAGINAL402 mgExact identifier — unii candidate
30 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPSYSTEM / TRANSDERMAL6.09 mgExact identifier — unii candidate
30 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPSUSPENSION / OPHTHALMIC0.1 %w/wExact identifier — unii candidate
30 equally ranked IID candidates
HIGH DENSITY POLYETHYLENEHIGH DENSITY POLYETHYLENEUG00KM4WR7SYSTEM / TRANSDERMALNAExact identifier — unii candidate
18 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPPASTE / TOPICAL47.5 %w/wExact identifier — unii candidate
30 equally ranked IID candidates
HIGH DENSITY POLYETHYLENEHIGH DENSITY POLYETHYLENEUG00KM4WR7OINTMENT / TOPICAL94 %w/wExact identifier — unii candidate
18 equally ranked IID candidates
HIGH DENSITY POLYETHYLENEHIGH DENSITY POLYETHYLENEUG00KM4WR7PASTE / DENTAL60 mgExact identifier — unii candidate
18 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPSPRAY / TOPICAL1379 mgExact identifier — unii candidate
30 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPSOAP / TOPICAL0.82 %w/wExact identifier — unii candidate
30 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPGEL / TOPICAL2.5 %w/wExact identifier — unii candidate
30 equally ranked IID candidates
HIGH DENSITY POLYETHYLENEHIGH DENSITY POLYETHYLENEUG00KM4WR7JELLY / VAGINAL42.6 %w/wExact identifier — unii candidate
18 equally ranked IID candidates

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 5 · 81 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
nystatinNYSTATINNuCare Pharmaceuticals,Inc.05cc72dd-8e05-bfb5-e063-6394a90a92f12026-08-19Adverse reactionsName fallback
generic name: NYSTATIN
nystatinNYSTATINPreferred Pharmaceuticals Inc.197e3046-3e58-4246-b260-f3995dce41a12026-08-05Adverse reactionsName fallback
generic name: NYSTATIN
NystatinNYSTATINPreferred Pharmaceuticals Inc.d92f67a7-dcae-41c0-9a35-dbafa23611702026-08-04Adverse reactionsName fallback
generic name: NYSTATIN
NystatinNYSTATINA-S Medication Solutions98bd8ccb-0c68-47b9-bcb4-c5d8217868d92026-07-24Adverse reactionsName fallback
generic name: NYSTATIN
NystatinNYSTATINPAI Holdings, LLC dba PAI Pharma28b4e26e-206a-4e8a-abfe-774b780e91c32026-07-21Adverse reactionsName fallback
generic name: NYSTATIN
NystopNYSTATINBryant Ranch Prepack0bb31239-fb77-442a-a9ee-ba61b45e7e682026-07-14Adverse reactionsName fallback
generic name: NYSTATIN
NystatinNYSTATINBryant Ranch Prepack2d2c4f79-95b5-417e-b5c1-8fac1dd09ddc2026-07-09Adverse reactionsName fallback
generic name: NYSTATIN
NystatinNYSTATINPreferred Pharmaceuticals Inc.a97b4fa6-c1a7-4003-9321-3717eb640ea92026-07-06Adverse reactionsName fallback
generic name: NYSTATIN
NYSTATINNYSTATINKesin Pharma Corporation50737729-a4a4-e747-e063-6394a90adcc52026-06-30Adverse reactionsName fallback
generic name: NYSTATIN
NYSTATINNYSTATINBryant Ranch Prepack4f6f59fb-ae7d-48e5-b23e-a1d92160974f2026-05-11Adverse reactionsName fallback
generic name: NYSTATIN
NystatinNYSTATINTorrent Pharmaceuticals Limited4949dea7-d2b9-4e0d-974a-39408fa174ba2026-05-08Adverse reactionsName fallback
generic name: NYSTATIN
NYSTATINNYSTATINGenus Lifesciences Inc.b25cbae5-eaf5-4501-b013-02c778ca4a4e2026-05-07Adverse reactionsName fallback
generic name: NYSTATIN
NystatinNYSTATINTorrent Pharmaceuticals Limited559b5bd4-3564-4437-8d0a-fa3a972f8b832026-05-01Adverse reactionsName fallback
generic name: NYSTATIN
MycostatinNYSTATINDirect_Rxf1857ac0-806c-4a7e-e053-2995a90abbc02026-03-17Adverse reactionsName fallback
generic name: NYSTATIN
NystatinNYSTATINA-S Medication Solutionsf1b13a36-c349-4e26-a322-3ec02c6101552026-03-16Adverse reactionsName fallback
generic name: NYSTATIN
NystatinNYSTATINChartwell RX, LLC9954118e-abe6-4388-98c9-4473d39b2e282026-03-05Adverse reactionsName fallback
generic name: NYSTATIN
NystatinNYSTATINCardinal Health 107, LLCd59098da-1395-49fb-9fd6-947bbbeed56f2026-02-26Adverse reactionsName fallback
generic name: NYSTATIN
NystatinNYSTATINMajor Pharmaceuticals17b9e33d-da9c-467a-bbc4-9e257727f19a2026-02-23Adverse reactionsName fallback
generic name: NYSTATIN
Nystatin Oral SuspensionNYSTATINXttrium Laboratories, Inc.4a670371-d373-1ba6-e063-6394a90a13b62026-02-06Adverse reactionsName fallback
generic name: NYSTATIN
NystatinNYSTATINRedPharm Drug, Incf4c298d5-b012-7b56-e053-2a95a90a3d552026-01-24Adverse reactionsName fallback
generic name: NYSTATIN

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.